Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Atosiban
Overview
A competitive oxytocin/vasopressin V1a receptor antagonist used as a tocolytic agent to delay preterm labor. Atosiban blocks oxytocin-mediated myometrial contractions without the cardiovascular side effects associated with beta-adrenergic tocolytics.
Mechanism of Action
The peptide is administered as an initial bolus followed by a step-down infusion protocol over up to 48 hours.
Research Summary & Key Findings
Approved in Europe and many countries worldwide (not FDA-approved in the US). Clinical trials demonstrated efficacy in delaying delivery by 48 hours to allow corticosteroid administration for fetal lung maturity. Superior safety profile compared to beta-agonist tocolytics, with significantly fewer maternal cardiovascular side effects (Flenady et al., Cochrane Review, 2014).
Clinical Status
Atosiban is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Atosiban"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Atosiban"
Registered interventional and observational studies, including status and phase.
- PubChem: "Atosiban"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Reproductive
Leuprolide (Lupron)
FDA ApprovedA synthetic nonapeptide GnRH agonist approximately 15-fold more potent than native GnRH. After an initial stimulatory ph...
View detailsGoserelin (Zoladex)
FDA ApprovedA synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug r...
View detailsCetrorelix (Cetrotide)
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, producing immediate and dose...
View detailsGanirelix
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph...
View detailsNo lawful pathway today
Atosiban is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.